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Abstract

Purpose: To compare the efficacy of Problem-Solving Therapy (PST) with Supportive Therapy
(ST) to improve Targeted Vision Function in Age-Related Macular Degeneration (AMD).
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Design: Single-masked, attention controlled randomized clinical trial with outcome assessments
at 3 months (main trial endpoint) and 6 months (maintenance effects).

Participants: Patients with AMD (N = 241) attending retina practices.

Interventions: PST uses a structured problem-solving approach to reduce vision-related task
difficulty. ST is a standardized attention control treatment.

Main Outcome Measures: Targeted Vision Function (TVF); National Eye Institute Vision
Function Questionnaire - 25 plus Supplement (NEI VFQ); Activities Inventory (AI); and VisionRelated Quality of Life.

Results: There were no significant between-group differences in TVF scores at 3 months (p =
0.47) or 6 months (p = 0.62). For PST subjects, mean [standard deviation (SD)] TVF scores
improved from 2.71 (0.52) at baseline to 2.18 (0.88) at 3 months (p = 0.001) and were 2.18
(0.95) at 6 months (change from 3 to 6 months, p = .74). For ST subjects, TVF scores improved
from 2.73 (0.52) at baseline to 2.14 (0.96) at 3 months (p = 0.001) and were 2.15 (0.96) at 6
months (change from 3 to 6 months, p = .85). Similar proportions of PST and ST subjects had
less difficulty performing a TVF goal at 3 months (77.4% vs. 78.6%, respectively; p = 0.83) and
6 months (76.2% vs. 79.1%, respectively; p = 0.61). There were no significant changes in the
NEI VFQ or AI. Vision-related quality-of-life improved for PST relative to ST subjects at 3
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months [F (4,192) = 2.46; p = 0.05] and 6 months [F (4,178) = 2.55; p = 0.05)]. PST subjects
also developed more adaptive coping strategies than ST subjects.

Conclusions: We found that PST was not superior to ST at improving vision function in patients
with AMD but PST improved their vision-related quality of life. Despite the benefits of antiVEGF treatments, AMD remains associated with disability, depression, and diminished quality
of life. This clinical reality necessitates new rehabilitative interventions to improve the vision
function and quality of life of older persons with AMD.

Key Words: Vision Function, Age-Related Macular Degeneration, Clinical Trial, Coping
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Introduction

Age-Related Macular Degeneration (AMD) is a chorioretinal disease that can lead to geographic
atrophy and choroidal neovascularization and hemorrhage.1 These advanced stages of AMD
account for most cases of severe vision loss in older adults and affect almost 2 million people in
the United States.2,3 Aging of the population will double the prevalence of AMD by 2020,
dramatically increasing the number of older adults who are visually impaired and at risk for
blindness, disability, depression, hip fracture, nursing homes residence, and reduced quality of
life.4-7 The anti-vascular endothelial growth factor (anti-VEGF) antibodies ranibizumab and
bevacizumab have greatly improved the prognosis of neovascular AMD but many patients
continue to have disabling vision impairment.8,9 For example, in the Minimally Classic/Occult
Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA),
about 35% of subjects had substantially improved vision function and 50% had improved mental
health but the converse is also informative: the vision function of 65% of subjects and the
mental health of 50% did not improve to that extent.8, 9 Patients with visual acuity worse than
20/70 in the better eye after treatment still have disabling impairment and rehabilitative needs.10
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Complementing the biomedical treatments for AMD are low vision rehabilitation (LVR)
interventions which maximize visual ability using vision-enhancing devices, environmental
modifications, and compensatory strategies.11 The recent VA Low Vision Intervention Trial
(LOVIT), a randomized controlled trial of outpatient LVR, demonstrated its efficacy to improve
reading and other functional abilities.12 Most visually impaired persons are unaware of LVR,
however, and few ophthalmologists are able to provide comprehensive vision care to their
patients.13 Without national policies to integrate ophthalmologic and rehabilitative care, patients
with AMD miss the opportunity to prevent disability, depression, and other medical
complications of vision loss.

To address this problem, we conducted a randomized, controlled clinical trial entitled,
“Improving Function in AMD” (IF-AMD), which compared the efficacy of Problem-Solving
Therapy (PST) with Supportive Therapy (ST) to improve Targeted Vision Function (i.e., ability to
perform valued vision-related daily living activities) in patients with AMD. PST teaches a
structured approach to problem-solving that we adapted to reduce vision-related task difficulty.14
ST is a structured, standardized, psychological treatment that controls for the nonspecific effects
of attention.15 In this clinical trial, we evaluated the immediate (3-months) and longer term (6months) efficacy of PST to improve the primary outcome of Targeted Vision Function and the
secondary outcome of vision-specific quality of life.
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Methods

The aim of the IF-AMD Trial was to test the efficacy of PST to improve the primary outcome of
Targeted Vision Function (TVF) in older patients with AMD at 3 months. We recruited 247
patients with AMD from the retina clinics associated with the Wills Eye Institute (WEI) in
Philadelphia, PA from October 2006 to February 2010. The inclusion criteria were: 1) age 65
years or older; 2) bilateral AMD (neovascular and/or geographic atrophy); 3) visual acuity
between 20/70 and 20/400 [inclusive; (best corrected)] in the better-seeing eye, and no lower

10

acuity limit in the fellow eye; and 4) moderate difficulty in at least one valued vision-function goal
(e.g., reading mail, attending social activities). The exclusion criteria were: 1) presence of
uncontrolled glaucoma, diabetic retinopathy, or planned cataract surgery within 6 months;
2) cognitive impairment on an abbreviated version of the Mini-Mental Status Examination
(MMblind) that omits vision-dependent items;16 3) presence of a medical condition that would
preclude participation; and 4) residence in a skilled nursing facility. Eligible subjects were
randomly assigned to PST or ST in a 1:1 allocation ratio stratified on severity of AMD (visual
acuity better vs. worse than 20/100 in the better eye). We used a random numbers table and
serially numbered, sealed, opaque envelopes containing the treatment allocations to assign
subjects within each stratum. The randomization schedule was based on a permuted random
block design to ensure balance between treatment groups on time of subject enrollment. To
attain 80% power for a 2-sided alternative hypothesis using a F-test to compare the 2 treatment
groups at 3 months, we required 200 subjects (100 per group) to detect an effect size of 0.4.
We over-sampled by 20% to account for attrition, bringing the total sample size to 240. Staff
masked to treatment assignment was involved in central data collection; only the project
director, statistician, and therapists were aware of treatment assignment. Thomas Jefferson
University’s Institutional Review Board approved this study and all subjects signed an approved
informed consent form.
Study Treatments

Problem-Solving Therapy (PST): PST teaches problem-solving skills in a structured way to
enable a patient to systematically identify his or her problems, generate alternative solutions for
each problem, select the best solution, develop and conduct a plan, and evaluate whether the
problem is solved.14 In this study, the PST therapist and subject discussed the functional
problems caused by vision loss and used the following problem-solving steps to reduce the
difficulty of vision-dependent tasks: 1) clarifying the problems associated with the task;
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2) establishing a realistic goal toward improvement of task performance; 3) generating multiple
solution alternatives; 4) implementing decision-making guidelines; 5) choosing the preferred
solution(s); 6) implementing the preferred solutions(s); and 7) evaluating the outcome. The
PST therapist helped subjects to develop feasible solutions and reviewed available rehabilitative
services and devices to inform the process of generating solutions. The aim was to have
subjects incorporate the problem-solving method of reasoning as a routine, often-recruited
approach to solving future as well as current function-related problems.

Supportive Therapy (ST)

ST is a structured, standardized, psychological treatment that controls for nonspecific treatment
effects.15 ST resembles PST in all ways but for PST’s problem-solving skills training. Both
interventions are based on written treatment manuals and similar in dose and intensity of
attention (i.e. number and duration of sessions). ST is nondirective, supportive, and facilitates
personal expression and conveys empathy, respect, and optimism (i.e. a general sense that
things can get better). The ST therapist informs subjects that ST’s purpose is to explore the
impact of vision loss on their lives. The goals were to facilitate and deepen knowledge of
subjects’ life situations and their relationship to illness, disability, retirement, social isolation and
vision loss. The ST therapists created an accepting, non-judgmental, empathic environment by
using supportive statements, reflective listening, and empathic communications. In contrast to
PST, there was no discussion of vision function goals, problem solving, or low vision
rehabilitative strategies.

Fidelity, Supervision, Masking, and Adherence
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PST and ST therapists had bachelors or masters level degrees in the social sciences and were
trained by a clinical psychologist (MTH) to deliver both interventions to reduce therapist effects.
Both PST and ST are manual driven treatments; thus training concentrated on properly adhering
to the treatment manuals. The training program consisted of workshops, review and discussion
of the treatment manuals, and supervision of 5 training cases. All therapists met satisfactory
levels of competence before delivering study treatments. To monitor treatment fidelity, all
treatment sessions were audio-taped and 30% were randomly selected for fidelity ratings. To
assess subjects’ adherence to PST, therapists rated whether PST subjects understood and
applied PST principles, complied with homework, and accomplished requisite problem-solving
tasks. ST subjects did not focus on vision goals or have homework as part of their treatment.
The research nurse who conducted outcome assessments became unmasked to the treatment
assignment of 9 subjects (3.7%) when the latter revealed their assignments.

Study Measures:
A research nurse masked to treatment assignment obtained the following data during in-home
interviews at baseline and months 3 and 6.

Personal characteristics: These included age, sex, race, marital status, living arrangements,
and education.

Primary Outcome: To assess the primary outcome of vision function, we identified and
quantified the Targeted Vision Function (TVF) goals that subjects valued but found difficult to
achieve. To derive the TVF measure, at baseline subjects completed the Activities Inventory,
which is a structured vision function questionnaire that asks patients to rate the value and
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difficulty of 48 vision function goals (e.g., daily meal preparation) and the tasks (e.g., seeing
stove settings) that are required to achieve them.17,18 If a goal is important (range not important
“0” to very important “4”), the subject rates its “difficulty” [on a scale of 0 (not difficult) to 4
(impossible)]. The average TVF score is the sum of the difficulty ratings of the (up to) 4 selfselected goals divided by the number of goals (from 1 to 4). Higher average scores indicate
greater disability. At each outcome assessment subjects again rated the difficulty of the same
targeted goals and the average TVF score was calculated. In this way, TVF was targeted and
tailored, measured in a standardized way, and allowed subjects to vary in the number of TVF
goals they select at baseline.

Secondary Outcomes: We administered the National Eye Institute Vision Function
Questionaire-25 plus Supplement (NEI VFQ).19 This version of the NEI VFQ consists of 39
items that assess self-reported vision function and vision-related quality of life (QoL). The latter
yields a multidimensional index of vision-related health comprised of social functioning (i.e.,
social interactions), mental health (i.e., worry, frustration), role difficulties (i.e., accomplishing
less), and dependency (i.e., relying more on others) due to vision loss. Scores range from 0 to
100, with higher scores indicating better function.

Vision Status: We assessed vision using a standardized battery of vision tests and
standardized lighting to assess distance and near visual acuity, contrast sensitivity, and the size
and location of central scotomas. To measure distance visual acuity, we used the Lighthouse
Ferris-Bailey Early Treatment Diabetes Retinopathy Study (ETDRS) chart at a distance of 10
feet. For near acuity we used a reduced version of the ETDRS chart calibrated for 40 cm. For
contrast sensitivity, we used the Pelli-Robson Contrast Sensitivity chart. To measure the size of
central scotomas we used a tangent screen and modified Amsler grid technique.
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Physical Health Status: We calculated the Chronic Disease Score, which provides an
objective measure of medical comorbidity based on a weighted sum of medications taken for
chronic illness.20 Higher scores indicate worse medical morbidity.

Psychosocial Status: To assess depression, we used the Patient Health Questionnaire-9,
which yields a continuous measure of depression severity.21 Scores range from 0 to 27, with
higher scores indicating worse depression. We used the Optimization in Primary and
Secondary Control Scale (OPS) to assess subjects’ control (i.e., coping) strategies.22-24 The
OPS is divided into 4 control strategies, each comprised of 8 items rated from 0 (“never true”) to
4 (“almost always true”), yielding a range of 0 to 32; higher scores indicate greater use of the
particular strategy. Selective primary control refers to the investment of behavioral resources
(i.e., time, effort, skills) to pursue a goal (e.g., “I do whatever I can to continue my everyday
activities despite my vision problem.”). Selective secondary control serves to maintain
commitment to a goal in the face of obstacles (e.g., “I think how important it is to me to keep up
my daily activities in spite of my vision problem.”). Compensatory primary control refers to
asking for help from others or using assistive devices (e.g., “If I’m having trouble doing
something because of my vision problem, I look for a device or aid that will help get it done.”).
Compensatory secondary control refers to goal disengagement when goals become
unattainable (e.g., “I can accept that there are things I can no longer do since I started having
problems with my vision.”).

Data Analyses
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We used descriptive statistics and bivariate comparisons of subjects in the two treatment groups
to characterize the sample, and assess the success of randomization. To test the efficacy of
PST to improve TVF functional reserve measures at 3 months, we used an analysis of
covariance (ANCOVA) in which group differences (PST vs. ST) in 3-month average TVF scores
were examined, adjusting for baseline TVF score and the vision severity stratification variable.
To approximate an interval scale and compensate for ceiling and floor effects, we linearized
TVF scores using a logit transform.24 We also conducted subsidiary analyses examining
treatment group effects on total NEI VFQ scores and AI measures estimated from Rasch
analysis. We repeated all analyses to assess the maintenance effects of the study treatments
at 6 months. To determine whether PST and ST were associated with clinically meaningful
changes in function, we compared the proportions of subjects in the two treatment groups who
rated a TVF goal at 3 or 6 months as less difficult compared with baseline. To determine PST’s
impact on vision-related quality-of-life at 3 and 6 months (in separate analyses), we used a
multivariate analysis of covariance (MANCOVA) in which the dependent variables were the
NEI-VFQ social functioning, mental health, role difficulties, and dependency subscales, with the
visual acuity stratification variable and baseline NEI-VFQ scores as covariates. We analyzed
rank-transformed scores because the distribution of scores was highly skewed. Mixed effects
linear regression was used to model change in TVF and Optimization of Primary and Secondary
Control variables over time. Fixed effects included time (baseline, 3 months, 6 months),
treatment group, time by treatment interaction, and the vision severity stratification variable. A
first-order auto-regressive structure was assumed to model the correlation among repeated
measurements from the same subject.
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Results
Figure 1 depicts the study flow chart. A total of 1,155 patients met ophthalmologic eligibility
criteria and were approached for further screening. Of these, 247 (21%) were enrolled and 914
(79%) were excluded. Of the latter, 414 (36%) refused participation; 214 (19%) did not have
difficulty achieving valued goals; 12 (1%) were deceased; and 273 (24%) had other reasons
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(e.g., could not be reached, medical illness, cognitive impairment). Six enrolled subjects
dropped from the study prior to randomization. Two hundred eleven subjects (87.6%) had
neovascular disease in at least one eye; the remainder had bilateral geographical atrophy. In
the better vision stratum (i.e., better eye acuity 20/70 – 20/100), there were 76 PST and 73 ST
subjects. In the worse vision stratum (better eye acuity <20/100), there were 45 PST and 47 ST
subjects. The attrition rates at 3 months for PST and ST subjects were 12% and 7%,
respectively; at 6 months they were 13% and 9%, respectively. At baseline, 53% of PST
subjects and 46% of ST subjects reported previously receiving anti-VEGF treatment. At 3
months, 48% of PST and 40% of ST subjects reported receiving injections after the baseline
assessment, and 43% of PST and 42% of ST subjects reported receiving injections between the
3 and 6 month assessments.

Table 1 compares the demographic and clinical baseline characteristics of randomized subjects
by treatment group. Notable are the advanced age of the subjects (average age about 82
years) and the severity of their vision loss. The average near visual acuity in the better-seeing
eye (logMAR score of 0.62) corresponds to a Snellen visual acuity of about 20/80. Subjects in
the PST and ST groups identified similar valued vision function goals to address in treatment:
read newspaper (48% in both groups; leisure/entertainment activities: 38% and 48%,
respectively; correspondence: 31% and 23%, respectively; personal communication: 31% and
23%, respectively; and manage finances: 22% and 21%, respectively. PST and ST subjects
received a similar number of treatment sessions [5.8 (.8) and 5.9 (.5), respectively]. PST
subjects addressed a mean of 4.5 (1.6) vision function goals. Over the 6 month study period
there were no significant within or between group changes in visual acuity, contrast sensitivity,
or scotoma size (data not shown).
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Table 2 shows the primary and secondary outcomes by treatment group at baseline and 3 and 6
months. For PST subjects, mean [standard deviation (SD)] TVF scores (primary outcome)
improved from 2.71 (0.52) at baseline to 2.18 (0.88) at 3 months (p = 0.001) and were 2.18
(0.95) at 6 months (change from months 3 to 6, p = .74). For ST subjects, TVF scores improved
from 2.73 (0.52) at baseline to 2.14 (0.96) at 3 months (p = 0.001) and were 2.15 (0.96) at 6
months (change from 3 to 6 months, p = .85). There were no statistically significant betweengroup differences at 3 months (p = 0.47) or 6 months (p = 0.62). The results were the same
using transformed TVF scores (data not shown). Similar proportions of PST and ST subjects
experienced less difficulty performing a TVF goal at 3 months (77.4% vs. 78.6%, respectively; p
= 0.83) and 6 months (76.2% vs. 79.1%, respectively; p = 0.61).

On the secondary multivariate outcome of vision-related quality-of-life (i.e., a composite of the
NEI VFQ-25 social functioning, mental health, role difficulties, and dependency subscales),
there was a significant treatment group difference at 3 months favoring PST [F (4,192) = 2.46; p
= 0.05] that was maintained at 6 months [F (4,178) = 2.55; p = 0.05]. On the secondary
outcomes of total NEI VFQ-25 scores and Activity Inventory scores, there were no significant
between-group or within-group changes from baseline to 3 months or from 3 months to 6
months. Levels of depression (i.e., PHQ-9 scores) were very low at baseline; there was no
significant changes in depressive symptoms in either treatment group over time. There were
also no statistically significant changes or treatment group differences in the use of low vision
devices resources (e.g., device use, home modifications, or low vision rehabilitation).

Table 2 also shows mean scores on the Optimization of Primary and Secondary Control
subscales by treatment group at 3 and 6 months. Treatment group differences in two control
strategies, Compensatory Secondary Control and Selective Primary Control, indicate that

19

subjects who received PST developed more adaptive coping strategies than subjects who
received ST. For Compensatory Secondary Control, ST subjects had a significant decline in
this coping strategy from baseline to 3 months (p ≤ 0.0001) and to 6 months (p = 0.015). This
suggests that ST subjects’ ability to disengage from goals when they were no longer attainable
declined (i.e., they were less accepting of vision loss) whereas PST subjects had no significant
changes in this strategy over time (3 months; p ≤ 0.92) and 6 months; (p ≤ 0.66). The
comparison of PST vs. ST subjects on change in this variable was significantly different at both
3 months (p = 0.01) and 6 months (p = 0.04). These data indicate that PST subjects’ use of
“acceptance” to compensate for vision loss remained stable over time whereas ST subjects’ use
of this strategy declined. On the control strategy of Selective Primary Control, which refers to
devoting time, effort, and skills to pursue a goal, PST subjects decreased use of this strategy
from baseline to 6 months (p = 0.0007) whereas ST subjects did not (p = 0.69). The between
group comparison was significant (p = 0.03). This finding suggests that PST subjects were less
likely than ST subjects to invest time and effort to pursue goals that they likely could not attain,
and is congruent with PST subjects’ acceptance of disability as per their greater use of
Compensatory Secondary Control noted above.

Discussion:

We found that PST was not superior to ST at improving the vision function of older patients with
AMD but PST did increase the use of adaptive coping strategies and improve vision-related
quality of life. As a “talking treatment,” PST emphasized independent problem solving but did
not directly advise on low vision rehabilitative interventions. We believe that this characteristic
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of PST limited its effectiveness to improve vision function. Although most subjects adhered to
the treatment plans that they devised, the latter were insufficient to reduce their functional
deficits. The significant changes in coping strategies that we observed suggest, however, that
the problem-solving approach may have helped PST subjects regain a sense of control over
their situation by developing realistic appraisals of their disability, disengage from goals that
they could no longer attain, free them to pursue goals that they could attain, and improved the
quality of their lives.

The patients we studied had bilateral AMD and high levels of visual disability. Although such
patients are common in clinical practice, they are not representative of most patients with AMD
given our eligibility criteria and high refusal rate. These factors introduce possible selection
biases and limit generalizability. Nevertheless, the average NEI VFQ scores in the sample were
comparable to subjects enrolled in MARINA (Minimally Classic/Occult Trial of the Anti-VEGF
Antibody Ranibizumab in the Treatment of Neovascular AMD), indicating the general similarity
of the two AMD patient groups.9 The strengths of the study include systematic sampling,
successful recruitment, randomization, and masking, protocol-driven treatments, assessment of
multiple relevant outcomes, and maintenance of treatment fidelity. We enrolled a sufficient
number of subjects to ensure adequate power to detect treatment effects on the primary
outcome.
Our approach to assess vision function recognized that no single, universally accepted measure
or methodology exists. Instruments such as the NEI-VFQ tap several diverse dimensions of
vision loss (e.g., difficulty with daily activities, social functioning, and quality of life) but may be
insensitive to the effects of interventions that target personally valued goals. Achieving these
goals, which may be meaningful to an individual, may not translate to a statistically significant
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change on a multi-item, multi-dimensional rating instrument. For that reason we used both a
targeted outcome approach (i.e., TVF) as well as the NEI VFQ to detect changes in vision
function. The TVF approach asked subjects to rate the difficulty of specific vision-dependent
goals that they valued and wished to address in treatment. Although we believed that this
approach was conceptually sound, we found that subjects’ ratings of difficulty levels were
inconsistent. In a subsample of 108 subjects, we reassessed TVF difficulty ratings two weeks
after baseline (before receiving any treatment) and found that the intraclass correlation between
the baseline and 2 week ratings was 0.45 (p < .001). In fact, 16 subjects (14.8%) changed their
first goal’s difficulty rating from “moderate or greater” at baseline to “slightly or not difficult” on
re-test 2 weeks later; 11 subjects (10.2%) changed their first goal’s difficulty rating from
“moderate” at baseline to “very difficult” or “impossible to do” on re-test. These data suggest
that TVF difficulty ratings were unstable. Although TVF scores declined in both treatment
groups over time, this within-group finding may reflect regression to the mean or a nonspecific
positive effect of study participation.

The IFAMD trial adds to other studies demonstrating the value of psychosocial and rehabilitative
treatments. Brody et al (2002) found that an AMD self-management program improved
function, decreased emotional distress, and enhanced self-efficacy, particularly for depressed
patients.25 We previously reported that PST prevented depression and improved vision function
in patients with recent vision loss due to AMD although its effect was short-lived because, we
believe, PST did not increase use of low vision rehabilitation devices or services.26 Likewise, in
the this clinical trial, PST did not increase subjects’ use of low vision resources even though
PST therapists reviewed available devices and services. These findings are important in light of
the VA Low Vision Intervention Trial (LOVIT), which demonstrated the efficacy of LVR to
improve the functional visual ability of moderately-to-severely visually impaired outpatients.12
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To improve vision function, we believe that an intervention that activates subjects and directly
enhances rehabilitative skills is needed. We are currently conducting the “Low Vision
Depression Prevention Trial,” which tests the efficacy of a low vision intervention that combines
rehabilitative and psychological treatments to prevent depression and improve function in
patients with AMD.27 Taken together, the clinical and public health significance of these studies
is clear: the disability of AMD will become more prevalent, costly, and burdensome to patients,
families, and ophthalmologists as the population ages. Despite the unprecedented benefits of
anti-VEGF treatments, AMD remains associated with disability, depression, and diminished
quality of life in some patients.8-10, 28 These clinical realities necessitate devising and testing new
rehabilitative interventions to improve the visual function and quality of life of older persons with
AMD.
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